STAT+: Patient advocates clash over wisdom of ‘approving drugs faster and faster’
NEW YORK — Over 30 years ago, Gregg Gonsalves and other AIDS activists persuaded Congress…
Category: STAT+
STAT+: Nvidia says generative AI will revolutionize health care. So did IBM, with Dr. Watson
The health care sector is a notorious laggard when it comes to technology. It was…
STAT+: During the pandemic, were great vaccines bad business? A company-by-company review
It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people…
STAT+: How biotech investors spot opportunity when stocks are down — and up
Following a blockbuster year of dealmaking and a recent uptick in biotech stocks, top investors…
STAT+: How a for-profit health system’s push to expand ended in disappointment for a tiny island nation
Protesters in the tiny Mediterranean nation of Malta converged last October on the 18th-century Baroque palace…
STAT+: Despite new Wegovy coverage, Medicare patients may face high drug costs and other hurdles
Medicare confirmed this week that it will cover Novo Nordisk’s obesity drug Wegovy if prescribed…
STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, FDA syringe warnings, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Drug development was once a marathon. New tools and timelines are turning it into a sprint
Drug development is more of a sprint than a marathon these days, thanks to more…
STAT+: Hospitals turn to sports performance centers to offer athletes elite care — for the right price
FOXBOROUGH, Mass. — Jodi Cullity calls herself a pickleball fanatic. The 29-year-old is the founding…
STAT+: Ibogaine, the psychedelic, unlikely to receive approval as opioid treatment, says top addiction researcher
The psychedelic ibogaine is unlikely to ever receive approval as a treatment for opioid addiction,…
STAT+: Regeneron’s plot to ‘cure’ allergies
George Yancopoulos is in touch with his teenage self. After 35 years as head scientist…
STAT+: Feng Zhang suggests Editas didn’t move quickly enough to find product targets
When the first biotech companies emerged to capitalize on the revolutionary genome-editing technology CRISPR, Editas…
STAT+: Digital tools for diabetes management did not deliver benefits that justify cost, new report finds
The last decade has seen billions of dollars flow into digital health companies that promise…
STAT+: Gene-edited pig kidney transplanted into a living patient for the first time
In a new test of xenotransplantation, a medical team at Massachusetts General Hospital announced Thursday…
STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, GSK asthma inhalers, and more
Top of the morning to you, and a fine one it is. Although quite chilly…
STAT+: Prometheus team launches new startup with $400 million to tackle immune-driven disorders
What happens after you close a nearly $11 billion acquisition? Well, for Prometheus Therapeutics’ former…
STAT+: Pharma companies and their allies seek to exempt orphan drugs from state pricing limits
As more states create dedicated boards to cap the costs of medicines, some drugmakers and…
STAT+: U.K. health officials and researchers try to carve a path for more individualized genetic treatments
LONDON — Widespread genetic testing as well as the development of cutting-edge, customized genetic therapies…
STAT+: A preview of Intra-Cellular Therapies’ depression drug, and sizing up the MASH opportunity
I am one week away from the launch of my weekly email newsletter! It’s called…
STAT+: Medicare expected to negotiate obesity drug prices soon, new analysis predicts
WASHINGTON — Medicare will likely choose the obesity drug semaglutide for price negotiation “within the…
STAT+: Pharmalittle: We’re reading about Europe’s pharma reform, weight-loss meds, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: J&J sues former employee for allegedly taking thousands of documents to a new job at Pfizer
Johnson & Johnson has accused a long-standing employee of taking thousands of confidential files about…
STAT+: Immuno-oncology startup launches with $150 million, ex-Surface, Bluebird exec as CEO
Robert Ross had thought he would take more time off after his previous company, Surface…
STAT+: New gene therapy, to be priced at $4.25 million, has already transformed children’s lives
Every morning, Victoria Rasberry gets up before 6 a.m., walks to the bedroom down the…
STAT+: A scientific mystery highlights the blind spots in genomics databases
The two patients had both died young from heart problems. When researchers looked at their…
STAT+: UnitedHealth appears to be upping loan offers to providers, after Change cyberattack
UnitedHealth Group appears to be offering some providers more substantial loans in the wake of…
STAT+: In small study, baby aspirin cuts fat buildup in liver disease patients
Low-dose aspirin led to a reduction in liver fat among patients with metabolic-associated liver disease,…
STAT+: Pharmalittle: We’re reading about an AstraZeneca deal, a WHO pandemic pact, and more
Rise and shine, everyone, another busy day is on the way. Already, the official mascots…
STAT+: Q&A: Mark Parrino says it’s time to ‘completely re-examine’ methadone treatment for opioid addiction
Nobody has made more of an impact on methadone treatment than Mark Parrino. For decades,…
STAT+: The methadone clinic monopoly: Opioid treatment chains backed by private equity are fighting calls for reform
Private equity firms have acquired stakes in nearly one-third of all methadone clinics in recent…
STAT+: As targeted radiation field heats up, AstraZeneca to pick up Fusion Pharmaceuticals in $2 billion deal
LONDON — AstraZeneca said Tuesday it would acquire Fusion Pharmaceuticals in a deal worth more…
STAT+: FDA approves first gene therapy for a fatal neuron disease in children
The Food and Drug Administration on Tuesday approved a gene therapy for metachromatic leukodystrophy, a…
STAT+: I was wrong about Geron’s blood cancer drug. Now, is it a takeover target?
I was wrong about Geron. For years, I’ve believed — and declared publicly — that…
STAT+: Pharmalittle: We’re reading about CAR-T drugs for myeloma, CVS rebate credits, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: As AI marches into medicine, investors eye security, privacy startups
Investors are starting to back startups that offer privacy and security services to bolster health…
STAT+: As Humira biosimilars take over the market, CVS has created a new ploy: the drug ‘rebate credit’
The biggest enticement that large pharmacy benefit managers offer to the employers that hire them…
STAT+: The Boston area built a ton of lab space. Now many of those buildings are opening empty
Around this time three years ago, while most of us navigated pandemic life, real estate developers…
STAT+: FDA advisers back CAR-T therapies in blood cancer, despite safety concerns
A panel of expert advisers to the Food and Drug Administration on Friday voted in…
STAT+: Pharmalittle: We’re reading about a liver-drug approval, pharma’s positive outlook, and more
And so, another working week will soon come to a close. Not a moment too…
.jpg)
STAT+: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline
German pharmaceutical company Bayer is expanding its U.S. pharma business significantly, despite corporate turmoil and…
STAT+: Madrigal wins first U.S. approval for drug to treat liver disease MASH
The Food and Drug Administration on Thursday approved the first medicine developed specifically to treat…
STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Vertex hits speed bump in getting CRISPR sickle cell therapy covered in U.K.
LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based…
STAT+: AstraZeneca picks up rare-disease focused Amolyt Pharma in $1 billion deal
LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal…
STAT+: Medicare couldn’t cover Wegovy for weight loss. But now that it’s also a heart drug, the door is open
WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug…
STAT+: Q&A: Amid AI frenzy in medicine, a federal regulator’s quest to create safeguards
Micky Tripathi is equal parts excited — and deeply concerned — about the technological change…
STAT+: Argenx readies another blockbuster opportunity with its antibody drug
Have you heard the news? I’m launching a weekly email newsletter starting on March 28….
STAT+: BIO severs ties with WuXi in the face of U.S. government concerns over China
WASHINGTON — The Biotechnology Innovation Organization, an industry trade group, is cutting ties with Chinese…
STAT+: RaDonda Vaught, former Vanderbilt nurse who accidentally killed patient, says hospital issues contributed, too
Speaking before a virtual audience of CommonSpirit Health employees, RaDonda Vaught, the former nurse who…
STAT+: Small studies offer hope CAR-T can fight an aggressive brain cancer
A series of new studies are raising hopes that CAR-T, a process in which treatments…